Tag: pharmaceuticals

  • Group to Develop Cell Therapy Industry Standards

    The International Society for Cellular Therapy (ISCT) in Vancouver, Canada has rechartered an industry committee to develop standards for business processes that lead to late-stage clinical trials. ISCT expects larger health care and pharmaceutical companies to participate in this group. According to Ed Horwitz, M.D., President of ISCT, the group — called the ISCT Industry…

  • FDA Fast-Tracks Treatment for Hepatitis C Infection

    Pharmasset Inc., in Princeton, New Jersey, received a fast-track designation from the U.S. Food and Drug Administration (FDA) for its drug PSI-7977, developed for the treatment of chronic hepatitis C virus (HCV) infection. PSI-7977 is an oral nucleotide analog inhibitor of HCV. Pharmasset recently completed dosing in a Phase 2a trial to evaluate PSI-7977 in…

  • FDA Committee Advances Anti-Epileptic Drug

    GlaxoSmithKline in Research Triangle Park, North Carolina and Valeant Pharmaceuticals International in Aliso Viejo, California announced that a U.S. Food and Drug Administration (FDA) advisory committee voted that clinical studies offered substantial evidence of the effectiveness of the companies’ drug ezogabine as an added treatment for adults with partial-onset seizures. The FDA’s Peripheral and Central…

  • Patent Awarded for Low Testosterone Treatment

    Repros Therapeutics Inc. in the Woodlands, Texas announced the U.S. Patent and Trademark office has issued a patent for Androxal, the company’s lead treatment for low testosterone in men. This patent claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism, when the sex glands produce little or no hormones.…

  • New Standard Advanced for Labeling on Injectable Medications

    An expert committee of the United States Pharmacopeia (USP), a standards–setting body for prescription and over–the–counter medicines, has advanced a new labeling standard for injectable products, to reduce the likelihood of errors in the administration of these drugs. The new standard, to be published on 1 November 2010, applies to the top (circle) surface of…

  • Cypress Bioscience to Cut Business Lines, Slash Workforce

    Cypress Bioscience in San Diego, California announced today several cost-cutting measures including a sharp reduction in staff. The steps announced will end a co-promotion agreement with Forest Laboratories, and close the company’s personalized testing services. The drug development company discontinued an agreement with Forest Laboratories to co-promote Savella, its drug for fibromyalgia, a disorder causing…

  • FDA Approves Drug for Neurological Movement Disorders

    According to Merz Pharmaceuticals in Greensboro, North Carolina, the U.S. Food and Drug Administration (FDA) has approved its drug Xeomin for the treatment of adults with cervical dystonia or blepharospasm, disorders characterized by involuntary, sustained muscle contractions. Merz Pharmaceuticals says the FDA approved the drug, with the generic name incobotulinumtoxinA, based on results from two…

  • Biotech Company to Partner with Scripps on Parkinson’s Drugs

    Envoy Therapeutics Inc., a drug discovery company in Jupiter, Florida says it has begun a research collaboration with The Scripps Research Institute to identify new drugs for Parkinson’s disease that have greater efficacy and safety compared to current therapies. Using funding provided by Envoy, scientists at the two organizations will apply Scripps-Florida’s screening facilities —…

  • Clinical Trial Shows Drug Impact on Fragile X Syndrome

    A drug made by Seaside Therapeutics Inc. of Cambridge, Massachusetts  has shown results controlling symptoms of fragile X syndrome, an inherited disorder known to cause autism. The findings were reported  this past weekend at a meeting of the National Fragile X Foundation. The results of the randomized, double-blind, placebo-controlled Phase 2 clinical trial showed subjects…

  • Drug Discovery Company Cutting 30% of Staff

    Adolor Corporation, a drug discovery and development company in Exton, Pennsylvania will reduce its staff by 30 percent to meet an expected cash flow reduction over the next two years. The company specializes in pharmaceuticals for pain management. In its press release, Adolor says sales of its flagship product Entereg, developed for upper and lower…